1 Min Read
May 8 (Reuters) - Kite Pharma Inc
* Kite says one patient in safety study testing cancer drug, KTE-C19, developed multiple organ failure and then fatal cerebral edema: conf call Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.